Smith & Nephew expecting a Q4 underlying revenue decline of approximately -7%

Smith & Nephew plc (LON:SN), the global medical technology business, has announced that it expects a fourth quarter underlying¹ revenue decline of approximately -7%. Sales were impacted by increased rates of COVID-19 infection from mid-October onwards, particularly in the US and Europe where more procedures were postponed following the reintroduction of restrictions.

As in previous months, the impact was most pronounced on our Orthopaedic Reconstruction, Sports Medicine and ENT businesses, driven by lower levels of elective surgery. Our Advanced Wound Management and Trauma businesses remained more resilient.

Full year underlying revenue is expected to have declined approximately
-12%. As previously stated, the trading profit margin will be substantially down year-on-year, with negative operating leverage due to lower volumes partially offset by cost control measures.

Throughout 2020 we continued to serve customers, develop and launch new products and make acquisitions, whilst prioritising the health and wellbeing of employees.

Further detail of the trading performance, including franchise and regional sales performance, trading profit margin, and a review of our strategic progress in 2020, will be provided with Smith & Nephew’s fourth quarter and full year results, scheduled for 18 February 2021.

Share on:

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:

Latest Company News

CLO income fund Volta Finance delivers 0.4% return in June, NAV at €7.46

In June 2025, Volta Finance achieved a net performance of +0.4%, lifting its cumulative return since August 2024 to +11.2%, with both CLO debt and equity assets posting gains amid easing trade tensions and stable credit markets, and ending the month with a NAV of €7.46 per share.

Thor Energy signs term sheet with Met1 for US project sale

Thor Energy has agreed a term sheet to sell 75% of its US uranium and vanadium subsidiaries to Met1 for a £100,000 exclusivity fee and £1 million in stock, retaining a 25% interest.

Global Opportunities Trust NAV at £110.7 m

As at 30 June 2025, Global Opportunities Trust reported net assets of £110.7 m with equity investments representing 64.6 % of the portfolio. Top holdings include the AVI Japanese Special Situations Fund (12.9 %) and Volunteer Park Capital Fund (7.0 %).

China-focussed UK stock FCSS reports 27% annual share price rise

China’s stimulus drove economic recovery, with stock selection in Hesai Group, LexinFintech and VNET adding value despite underweights in Xiaomi, Xpeng and Tuhu, while over the 12 months to 30 June 2025 the Trust’s NAV rose 28.0% and its share price gained 27.3%, outperforming the reference index’s 23.4%.

UK market a ‘rich pool of investment opportunities’, FSV Factsheet

UK equities delivered modest gains in June, supported by prospects of BoE rate cuts and a more constructive tariff outlook, despite a mid‑month risk‑off following US and Israel strikes on Iranian sites and subsequent relief from a ceasefire.

Fidelity Asian Values significantly outperforms its index over 1 year (LON:FAS)

Over the 12 months to 30 June 2025, the Trust’s NAV rose 4.9%, outperforming its reference index which fell 0.1%, while the share price gained 6.9%. Stock selection was the key driver, with contrarian positions in China and Australia and picks in materials and consumer staples adding value, though an overweight in Indonesian small caps detracted.